Xcout IntelBionano Genomics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Bionano Genomics, Inc. among biotech companies — ranked by similarity to what Bionano Genomics, Inc. actually does, not by market-cap band.
Subscribe to see Bionano Genomics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Bionano Genomics, Inc.
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
Bionano Genomics, Inc. at a glance
Bionano Genomics, Inc. is a biotech company headquartered in San Diego, United States. It is publicly listed (BNGO) with a market capitalisation of $16.5M. Xcout tracks 17 named people at Bionano Genomics, Inc., including Albert A. Luderer (Chairman, Interim CEO, Interim President & Interim Principal Financial Officer).
Bionano Genomics, Inc. leadership
- Albert A. LudererChairman, Interim CEO, Interim President & Interim Principal Financial Officer
- Albert LudererChairman & Interim CEO
- Mark OldakowskiChief Operating Officer
- Alex HastieChief Scientific Officer
- Mark AdamchakVP of Accounting, Principal Accounting Officer & Controller
- Cory KreeckGlobal Head of People Operations
11 more named people on record for Bionano Genomics, Inc., with roles, board committees and tenure — see the full roster →
Bionano Genomics, Inc. funding rounds on record
The most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $53M | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Bionano Genomics, Inc. competitors
Ranked by semantic similarity — how close each company is to Bionano Genomics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Illumina, Inc. specializes in delivering advanced sequencing and array technologies designed for genetic and genomic examination. These offerings cater to a diverse array of markets, fostering the widespread use of genomic insights across both research laboratories and clinical environments. Key application areas include life sciences, cancer diagnostics, reproductive medicine, agricultural science, and various nascent fields. The company's portfolio encompasses specialized instrumentation and associated consumables vital for genetic analysis. Additionally, it offers comprehensive genotyping and sequencing services, extends instrument maintenance contracts, and engages in development and licensing partnerships, alongside providing cancer screening services. Illumina's client base is extensive, comprising genomic research facilities, universities, state-funded laboratories, and healthcare providers. It also serves pharmaceutical firms, biotechnology companies, commercial molecular diagnostics providers, and businesses focused on consumer genomics. Globally, Illumina distributes its products through direct sales channels in North America, Europe, Latin America, and the Asia-Pacific. Furthermore, it leverages third-party life-science distributors to reach markets across Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Life Sciences
Biotrove, Inc., founded in 1997, is a developer and manufacturer of genomic analysis instruments, consumables, and technology platforms such as OpenArray. The company provides systems and services for molecular diagnostics, high-throughput screening, drug discovery, and life sciences research.
Biotechnology
Olink Proteomics provides high-throughput protein biomarker analysis products, instruments, software, and analysis services for life science research and drug development. Utilizing its proprietary Proximity Extension Assay (PEA) technology and next-generation sequencing, the company serves researchers and pharmaceutical organizations focused on biomarker discovery and precision medicine.
Similar biotech company
OraSure Technologies, Inc., together with its subsidiaries including DNA Genotek, develops and provides non-invasive diagnostic tests and biological sample collection tools. The company serves individuals, healthcare providers, and researchers by offering solutions for infectious disease detection, genomics, metabolomics, and microbiome research.
Similar biotech company
Source BioScience is a UK-based laboratory services company providing genomics, DNA sequencing, molecular diagnostics, and pathology-related testing. It serves pharmaceutical and biotechnology companies, healthcare organizations, research institutions, and other life-science customers.
Biotechnology, Diagnostics, Healthcare
GenDx specializes in molecular diagnostics for transplantation and personalized healthcare, providing pre- and post-transplant reagents, NGS-based typing assays, and analysis software. The company serves diagnostic laboratories, transplant centers, and researchers by offering products and technical support for HLA typing, chimerism monitoring, and related applications.
Life Sciences, Diagnostics
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Similar biotech company
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Biotechnology
Intus Biosciences develops proprietary microbiome analysis technology that combines patented science, long-read sequencing, and AI to deliver strain-level resolution of microbial data. The company serves healthcare providers, researchers, and consumers through clinical-grade profiling products like GutID and research partnerships aimed at drug development and biomarker discovery.
Biotechnology
Stilla Technologies is a European biotechnology company based in Paris, France, that specializes in multiplex digital PCR. The company accelerates the development of next-generation genetic tests and maintains global distribution partnerships.
Healthcare
Aagamiseq Technologies Private Limited is a deep-tech startup founded in 2024 and based in Bengaluru, India. The company develops next-generation automated biotechnology systems and diagnostic platforms utilizing solid-state micropore and nanopore technologies for single-cell and single-molecule applications.
Similar biotech company
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Bionano Genomics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Bionano Genomics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →